High-Dose Intravenous Immunoglobulin May Reduce Latent HIV Reservoir in Resting CD4+ Cells, Study Suggests (February 10, 2009)
A five-day course of high-dose intravenous immunoglobulin appears to somehow activate replication-competent HIV in the resting CD4+ cells of patients on HAART, ultimately leading to a reduction in those patients' latent HIV reservoirs, according to the results of a nine-patient study presented by Magnus Gisslén, M.D., Ph.D.
In The 16th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
An Update on the Present -- and Future -- of HIV Eradication (February 8, 2009)
Robert Siliciano, M.D., is one of the world's foremost researchers on the topic of HIV eradication. We caught up with him at CROI 2009 to discuss recent developments in the field, which has suddenly experienced somewhat of a renaissance of late.
In The 16th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
The Next Stage of HIV Eradication: Finding the Secret Reservoirs (February 8, 2009)
In adherent patients on fully suppressive HAART, viral replication has completely stopped, says Robert Siliciano, M.D., Ph.D. But the virus still lurks persistently in reservoirs -- one whose identity is known, and at least one whose identity remains a mystery.
In 16th Conference on Retroviruses and Opportunistic Infections, from The Body PRO